Could this be the secret to Pfizer's rebound strategy?
It could prove to be a case of better later than never for the healthcare giant.
The sizable yield comes with a concerning footnote. Just look at the rest of the story.
Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.
Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...
The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Shares of Pfizer Inc. PFE slipped 1.19% to $24.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 7,499.36 and the ...
Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...
By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...
Pfizer said on Thursday that finance chief Dave Denton will leave on August 15 to return to the consumer goods industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results